glp 1 agonists diabetes GLP-1 receptor are increasingly used to treat type 2 and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP-1 receptor agonists (GLP-1RAs): cardiovascular
Description
Commun Med 4 , 137 (2024)
For dichotomous outcomes, we calculated ORs and 95% CIs using the random-effects MantelHaenszel approach
doi: 10.1016/j.jacbts.2018.09.004 126 RizzoMNikolicDPattiAMManninaCMontaltoGMcAdamsBSet al
Sun, Y., Koyama, Y
Refs, references
This new line of pharmaceuticals maximizes the beneficial effects on energy and glucose metabolism while minimizing unwanted side-effects (Tschop and DiMarchi, 2012)
